EDP007

EDP007 is an investigational bispecific or multispecific antibody being developed by Genor Biopharma for the treatment of atopic dermatitis. It is part of the company's antibody-based biologics platform, which focuses on addressing unmet needs in autoimmune and inflammatory diseases. By utilizing a multispecific format, EDP007 is intended to inhibit multiple signaling pathways or cytokines that drive the chronic skin inflammation characteristic of atopic dermatitis, potentially offering improved efficacy over monospecific therapies. As of the current pipeline status, the specific molecular targets have not been publicly disclosed.